NEUROPATHOLOGY
Among the most exciting recent developments in biomedical science is the emergence of
CRISPR-Cas9 gene-editing technology. Since its introduction, CRISPR has transformed genetic
research by enabling precise modification of DNA sequences with unprecedented efficiency
not only to the technical delivery of diagnostic tests but also to quality management, method validation, service development and implementation of emerging technologies. As precision medicine becomes increasingly embedded in routine healthcare, biomedical scientists will remain central to ensuring that complex molecular information is translated into accurate and clinically meaningful diagnostic reports.
Life in an NHS neuropathology laboratory Neuropathology services support the diagnosis and management of a diverse range of neurological diseases, including brain tumours, neurodegenerative disorders, inflammatory conditions and neuromuscular diseases. Although patients may never directly encounter the scientists processing their samples, laboratory findings frequently influence critical clinical decisions. Every specimen
processed, every slide examined and every result authorised contributes to patient diagnosis and treatment planning. The Walton Centre serves a population of approximately 3.5 million people and represents one of the largest specialist neuroscience centres in the United Kingdom. Supporting such services requires highly skilled multidisciplinary teams working collaboratively to deliver accurate and timely diagnostics. The expertise present within specialist neuroscience laboratories has been developed through years of professional experience, mentorship and continual learning. These environments not only support patient care but also provide opportunities for scientific innovation, education and research. The increasing integration of
molecular diagnostics further emphasises the importance of investing
in specialist pathology services. Future advances in neuro-oncology will depend upon laboratories capable of delivering sophisticated genomic testing while maintaining the highest standards of quality and patient safety.
In summary The glioma tumour microenvironment represents one of the most important areas of contemporary neuro-oncology research. Increased understanding of the complex interactions between tumour cells, immune populations and molecular signalling pathways is transforming approaches to diagnosis, classification and treatment. The integration of histopathology, IHC and molecular diagnostics has fundamentally altered neuropathology practice. Modern neuropathology increasingly
requires expertise in molecular pathology, genomics and translational science alongside traditional laboratory skills. Biomarkers such as GFAP, Ki-67, IDH1, ATRX, EGFR, CD3, CD8 and CD68 are no longer viewed simply as laboratory stains; they provide important insights into tumour biology, prognosis and therapeutic response. Pathology is far more than a
laboratory discipline, it is a field where scientific discovery, technological innovation and patient care intersect. As molecular diagnostics, precision medicine and emerging technologies continue to evolve, biomedical scientists will remain central to advancing neuro-oncology and improving outcomes for patients affected by glioma; a transformation that has
August 2026
WWW.PATHOLOGYINPRACTICE.COM 31
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
